Phoenix Biotech Acquisition Corp.

As of June 13, 2025, the technical trend is mildly bearish with mixed signals, including a bearish weekly RSI and mildly bullish weekly MACD, suggesting caution due to prevailing short-term bearish tendencies.

Phoenix Biotech Acquisition Corp. is a micro-cap finance company with a recent net profit loss of $5 million and a market cap of $3 million. It has no dividend yield and a highly negative debt equity ratio.

As of Jun 18, Phoenix Biotech Acquisition Corp. has a market capitalization of 3.00 million and reported net sales of 0.00 million, with a net profit of -11.20 million over the last four quarters. The balance sheet shows shareholder's funds of -0.60 million and total assets of 7.50 million.